Copper deficiency myeloneuropathy: A clue to clioquinol-induced subacute myelo-optic neuropathy?

Neurology

Volumn 71, Issue 9, 2008, Pages 622-623

  Schaumburg, Herbert ^a   Herskovitz, Steven ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLIOQUINOL; IRON CHELATE; CHELATING AGENT; COPPER; ZINC;

ACRODERMATITIS ENTEROPATHICA; ALZHEIMER DISEASE; CHILDHOOD DISEASE; COLOR VISION; COPPER DEFICIENCY; CYANOCOBALAMIN DEFICIENCY; DRUG ABSORPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; EDITORIAL; EXPERIMENTAL ANIMAL; HUMAN; JAPANESE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OPTIC NERVE DISEASE; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SPASTICITY; SUBACUTE MYELOOPTIC NEUROPATHY; URINARY EXCRETION; ANIMAL; CHEMICALLY INDUCED DISORDER; METABOLISM; MYELINATED NERVE; NOTE; OPTIC NERVE; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; SPINAL CORD DISEASE;

ANIMALS; CHELATING AGENTS; CLIOQUINOL; COPPER; HUMANS; NERVE FIBERS, MYELINATED; OPTIC NERVE; OPTIC NERVE DISEASES; SPINAL CORD; SPINAL CORD DISEASES; ZINC;

EID: 52449097414     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000324620.86645.c1     Document Type: Editorial

References (11)

1. Konagaya M, Matsumoto A, Takase S, et al. Clinical analysis of long-standing subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J Neurol Sci 2004;218:85-90.
2. Schaumburg HH. Clioquinol. In: Spencer PS, Schaum-burg HH, eds. Experimental and Clinical Neurotoxicology, second edition. New York: Oxford University Press, 2000: 396-400.
3. Krinke G, Schaumburg HH, Spencer PS. Clioquinol and 2-5-hexanedione induce different types of distal axonopathy in the dog. Acta Neuropathol 1979;47:213-220.
4. Arbiser JL, Kraeft S, van Leeuwen R, et al. Clioquinol-zinc chelate: a candidate causative agent of subacute myelooptic-neuropathy. Mol Med 1998;4:665-670.
5. Neldner KH, Hambridge KM. Zinc therapy of acrodermatitis enteropathica. N Engl J Med 1975;292:879-882.
6. Finefrock AE, Bush AI, Doraswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc 2003;51:1143-1148.
7. Kumar N, Gross JB, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004;63:33-39.
8. Kumar N, Ahlskog JE, Klein CJ, Port JD. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology 2006;48:78-83.
9. Nations SP, Boyer PJ, Love LA, et al. Denture cream: an unusual source of excess zinc, leading to hypocupremia and neurologic disease. Neurology 2008;71:639-643.
10. Tjalve H. The aetiology of SMON may involve an interaction between clioquinol and environmental metals. Med Hypoth 1984;15:293-299.
11. Schleper B, Steurenburg HJ. Copper deficiency-associated myelopathy in a 46-year old woman. J Neurol 2001;248: 705-706.